We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84M
AUM Growth
-$31.4M
Cap. Flow
-$24.4M
Cap. Flow %
-29.07%
Top 10 Hldgs %
66.01%
Holding
53
New
14
Increased
7
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$5.79M
2
PFE icon
Pfizer
PFE
+$5.13M
3
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
4
LEGN icon
Legend Biotech
LEGN
+$3.26M
5
CAPR icon
Capricor Therapeutics
CAPR
+$2.58M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$8.55M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$6.66M
3
GPCR icon
Structure Therapeutics
GPCR
+$5.88M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$5.84M
5
ZLAB icon
Zai Lab
ZLAB
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
26
DELISTED
Avidity Biosciences
RNAM
$657K 0.78%
+22,271
New +$694K
CABA icon
27
Cabaletta Bio
CABA
$461M
$636K 0.76%
458,972
-363,321
-44% -$774K
PCVX icon
28
Vaxcyte
PCVX
$8.12B
$425K 0.51%
+11,264
New +$901K
KYTX icon
29
Kyverna Therapeutics
KYTX
$453M
$369K 0.44%
191,287
+9,110
+5% +$26.9K
OCUL icon
30
Ocular Therapeutix
OCUL
$1.96B
$310K 0.37%
+42,297
New +$325K
SDGR icon
31
Schrodinger
SDGR
$1.14B
$279K 0.33%
+14,114
New +$318K
IPSC icon
32
Century Therapeutics
IPSC
$406M
$220K 0.26%
462,963
– –
CPIX icon
33
CALL
Cumberland Pharmaceuticals
CPIX
$102M
$212K 0.25%
+50,000
New +$207K
LSB
34
DELISTED
LakeShore Biopharma
LSB
$74.5K 0.09%
30,792
– –
AXSM icon
35
Axsome Therapeutics
AXSM
$11.8B
– –
-4,268
Closed -$361K
DYN icon
36
Dyne Therapeutics
DYN
$3.92B
– –
-73,150
Closed -$1.72M
EYPT icon
37
EyePoint Inc
EYPT
$1.12B
– –
-49,375
Closed -$368K
FATE icon
38
Fate Therapeutics
FATE
$324M
– –
-1,379,556
Closed -$2.28M
GPCR icon
39
Structure Therapeutics
GPCR
$3.45B
– –
-216,811
Closed -$5.88M
IDYA icon
40
IDEAYA Biosciences
IDYA
$3.47B
– –
-227,102
Closed -$5.84M
INCY icon
41
Incyte
INCY
$23.4B
– –
-18,009
Closed -$1.24M
INSM icon
42
Insmed
INSM
$23.5B
– –
-35,966
Closed -$2.48M
KURA icon
43
Kura Oncology
KURA
$964M
– –
-157,959
Closed -$1.38M
LXEO icon
44
Lexeo Therapeutics
LXEO
$368M
– –
-52,616
Closed -$346K
NVCR icon
45
NovoCure
NVCR
$1.84B
– –
-286,970
Closed -$8.55M
ORIC icon
46
CALL
Oric Pharmaceuticals
ORIC
$1.11B
– –
-200,000
Closed -$1.61M
PTGX icon
47
Protagonist Therapeutics
PTGX
$9.06B
– –
-68,892
Closed -$2.66M
RZLT icon
48
Rezolute
RZLT
$444M
– –
-123,184
Closed -$604K
TIL icon
49
Instil Bio
TIL
$50.3M
– –
-148,017
Closed -$2.83M
TNGX icon
50
Tango Therapeutics
TNGX
$4.65B
– –
-474,955
Closed -$1.47M
1
2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Superstring Capital Management held 53 positions worth $84M, down 27% from $115M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Superstring Capital Management withdrew a net $24.4M in Q1 2025, closing 19 positions and reducing 9 holdings. Its most notable exit was NovoCure, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Verona Pharma worth $6.15M.

  • Superstring Capital Management's largest Q1 2025 buy was Verona Pharma: 96,821 shares worth $6.15M.
  • Superstring Capital Management added most to Legend Biotech in Q1 2025, an estimated $3.26M increase.
  • Superstring Capital Management's biggest Q1 2025 reduction was Oric Pharmaceuticals, cutting an estimated $6.66M.
  • Superstring Capital Management fully exited NovoCure in Q1 2025, selling an estimated $8.55M.
  • Superstring Capital Management's ten largest holdings make up 66% of its $84M portfolio in Q1 2025.
  • Superstring Capital Management opened 14 new positions and closed 19 in Q1 2025.
  • Superstring Capital Management's portfolio value fell 27% quarter-over-quarter to $84M.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.